# Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.

> **NCT06675214** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 586 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma
- De-escalation Therapy

## Interventions

- **DRUG:** Full course of PD-1/PD-L1 blockades
- **DRUG:** Cisplatin-based induction chemotherapy
- **RADIATION:** Standard-dose IMRT
- **RADIATION:** Gradient Fractionated IMRT
- **DRUG:** Concurrent Chemotherapy

## Key facts

- **NCT ID:** NCT06675214
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-30
- **Primary completion:** 2027-07-31
- **Final completion:** 2030-07-31
- **Target enrollment:** 586 (ESTIMATED)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06675214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06675214, "Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06675214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*